Indivior PLC announced the presentation of new data from three posters and one late-breaking oral presentation at the College on Problems of Drug Dependence 83rd Annual Scientific Virtual Meeting taking place June 21-24, 2021. Data presented include an assessment of substance use during COVID-19 in a sample of participants in recovery from opioid use disorder in the United States, a post-hoc analysis of the efficacy and safety of different maintenance doses of extended-release buprenorphine in participants who used opioids via the injection route, a study assessing the safety and tolerability of initiating extended-release buprenorphine after administration of a single dose of 4 mg transmucosal buprenorphine, and a real-world implementation study of extended-release buprenorphine in people with OUD in diverse community healthcare settings in Australia.1,2,3,4 Struggling with recovery from opioids: Who is at risk during COVID-19? (Oral presentation) assessed substance use during COVID-19 among those in recovery from Opioid Use Disorder. The study sought to identify individual-level factors associated with COVID-19-related impacts on recovery in 216 participants originally enrolled in the SUBLOCADE clinical program. During September 2020 through January 2021, the study asked participants how the COVID-19 crisis affected their recovery from substance use.1 Classification and Regression Tree analysis examined the association of 28 measures with self-reported impact of COVID on recovery, including demographic, and psycho-social factors. The main findings from the study were as follows: 26% of participants reported that COVID-19 had made recovery somewhat or much harder Past-month opioid use rate was higher among those who reported that recovery was harder compared to those who did not (51% vs. 24%) These findings suggest that a set of identified criteria in this study might be beneficial to monitor among those in recovery from OUD, particularly during large-magnitude crises and particularly when access to healthcare is reduced. Examining the benefit of RBP-6000 300 mg versus 100 mg maintenance dose in opioid injectors (Poster QA session) compared the efficacy and safety of SUBLOCADE 300 mg versus 100 mg maintenance doses in participants who used opioids via injection route, using the data collected during the pivotal phase 3 trial.2 Adults with moderate or severe OUD were randomized to SUBLOCADE monthly injections or placebo and studied for 24 weeks.2 Participants receiving SUBLOCADE were given 2 monthly injections of 300 mg, followed by 4 monthly maintenance doses of 100 mg or 300 mg over the course of the study. The main findings from the study were as follows: Opioid-injecting users experienced continued improvement in the proportion of participants achieving abstinence with the 300 mg maintenance dose; no significant improvement was noted with the 100 mg maintenance dose Higher retention rates during the maintenance dose period was observed for the opioid-injecting users who received 300 mg and for the opioid non-injecting users who received 100 mg2 The safety profiles of 300 mg and 100 mg maintenance doses appeared comparable, including potential hepatic safety events This post-hoc analysis suggests that although a maintenance dose of SUBLOCADE 100 mg may achieve sufficient efficacy and safety in most opioid non-injecting users, the benefit of the 300 mg maintenance dose is clinically relevant in opioid-injecting users. Initiating Monthly Buprenorphine Injection After Single Dose of Sublingual Buprenorphine evaluated opioid withdrawal symptoms, safety and tolerability of initiating SUBLOCADE 300 mg one hour after administering a single dose of 4 mg transmucosal buprenorphine. During this study, 26 participants received BUP-TM, 24 proceeded to SUBLOCADE injection, and 20 completed the study. After SUBLOCADE injection, withdrawal symptoms and opioid craving scores improved within 12h. Improvements were sustained for 4 weeks Two of the 24 participants experienced precipitated withdrawal. No participants had severe withdrawal No serious Treatment Emergent Adverse Events were observed, nor were any related to SUBLOCADE treatment The authors concluded that initiating SUBLOCADE 300 mg following a single 4 mg dose of BUP-TM show a safety profile similar to that observed with SUBLOCADE induction per current labeling.